ER+/PR+ breast cancer, common and hormone-responsive, offers a better prognosis and is key in treatment research advancements ...

PR+ breast cancer responds well to hormone therapy, underscoring the need for molecular insight and targeted treatment ...

It would be short-sided, erroneous and dangerous to think ill of mifepristone, which has several important applications,, M.D ...

Breast cancer is the second leading malignant disease in females worldwide. Over decades of research, breast cancer classification by molecular subtypes has ...

As genetic and biomarker tests become more common, so do new therapies that target specific tumor types and may lead to ...

People assigned female at birth have a predisposition for migraines, especially in adolescence and around menopause. Find a ...

HR+/HER2- breast cancer involves tumor cells that test positive for hormone receptors and negative for HER2 proteins. Cancer ...

For many women, finding out that they have breast cancer is the worst news they can receive. Even worse news is if the breast cancer is termed “triple-negative,” which is ...

Triple-positive breast cancer is a type of breast cancer that tests positive for estrogen receptors, progesterone receptors, and high levels of HER2 protein. Some types of breast cancer cells use ...

Copyright: © 2025 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.

In a surprising discovery, scientists have found that the heart possesses 'sweet taste' receptors, similar to those on our tongues, and that stimulating these receptors with sweet substances can ...

Summary: New research sheds light on how ketamine affects the brain by targeting a specific NMDA receptor subtype, GluN1-2B-2D. Scientists used electron cryo-microscopy to capture how ketamine binds ...